4 active not recruiting, 3 completed, 1 recruiting, 1 terminated. 6 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Myelodysplastic Syndrome With Excess Blasts-2: new trials by email Literature Review of Myelodysplastic Syndrome With Excess Blasts-2 trials Research Report on Myelodysplastic Syndrome With Excess Blasts-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS Fludarabine, Busulfan and Melphalan - Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Unknown | Ruijin Hospital | 59 | 2024-03-03 | 2024-03-21 |
| BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome BXCL701 - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 1 | Active not recruiting | Eric Stephen Winer, MD | 12 | 2023-02-02 | 2026-10-19 |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2021-08-09 | 2024-05-23 |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy Gilteritinib, Midostaurin - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 3 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 777 | 2019-12-20 | 2024-12-17 |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion - Leukemia, Myeloid, Acute, Refractory AML | Phase 1 / Phase 2 | Recruiting | Aptose Biosciences Inc. | 240 | 2019-03-11 | 2025-08-26 |
| A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy AG-120, Placebo for AG-120, AG-221 - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 3 | Active not recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 968 | 2019-03-01 | 2026-09-22 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, Pharmacological Study - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 72 | 2019-01-31 | 2026-09-18 |
| Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Cladribine, Cyclosporine, Cytarabine - Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2 | Phase 2 | Completed | University of Washington | 30 | 2016-09-22 | 2021-11-08 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 84 | 2015-03-23 | 2026-06-01 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 20 | 2014-04-10 | 2024-03-12 |
Leukemia, Myeloid, Acute (9) · Blast Crisis (3) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Hematologic Neoplasms (1) · Leukemia, Monocytic, Acute (1) · Primary Myelofibrosis (1) · Recurrence (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Leukemia (9) · Leukemia, Myeloid (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Bone Marrow Diseases (6) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Carcinogenesis (3) · Cell Transformation, Neoplastic (3) · Myeloproliferative Disorders (3) · Neoplastic Processes (3)
Whole-Body Irradiation (3) · fludarabine phosphate (3) · Cytarabine (2) · Melphalan (2) · Methotrexate (2) · Mycophenolic Acid (2) · Peripheral Blood Stem Cell Transplantation (2) · Tacrolimus (2) · Thiotepa (2) · merphos (2) · Azacitidine (1) · Busulfan (1) · CPX-351 (1) · Cladribine (1) · Cyclophosphamide (1)
Fred Hutchinson Cancer Center (3) · Stichting Hemato-Oncologie voor Volwassenen Nederland (2) · Aptose Biosciences Inc. (1) · Eric Stephen Winer, MD (1) · M.D. Anderson Cancer Center (1) · Ruijin Hospital (1) · University of Washington (1)
United States (7) · Australia (3) · Germany (3) · Spain (3) · Austria (2) · Belgium (2) · Finland (2) · France (2) · Ireland (2) · Lithuania (2) · Netherlands (2) · Norway (2) · Sweden (2) · Switzerland (2) · China (1)
Marie Bleakley (2) · B.J. Wouters (1) · Eric S Winter, MD (1) · Filippo Milano (1) · Luxiang Wang (1) · M. Raaijmakers, Prof. Dr. (1) · Mary-Elizabeth Percival (1) · Naval Daver, MD (1) · Tapan M Kadia (1)
2018 (2), P01CA018029 (2), R01HL121568 (2), 2023 (1), K23CA154532 (1), P30CA015704 (1), P50CA100632 (1)